Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An announcement from NuGen Medical Devices Inc ( (TSE:NGMD) ) is now available.
NuGen Medical Devices Inc. has launched a dedicated French-language e-commerce platform for its needle-free insulin-delivery device, InsuJet™, in collaboration with Sol-Millennium France. This initiative aims to address the growing diabetes challenge in France, where 4.33 million people were living with diabetes in 2022. By eliminating needle anxiety, InsuJet™ promotes earlier insulin use, potentially reducing healthcare costs and improving patient outcomes. The device, which has been well-received by the healthcare community, offers benefits such as faster insulin absorption and higher patient satisfaction, aligning with France’s demand for safer and more economical diabetes care.
More about NuGen Medical Devices Inc
NuGen Medical Devices Inc. is a leader in needle-free subcutaneous drug-delivery technology. The company develops next-generation needle-free devices, with its flagship product, the InsuJet™ system, designed to improve the lives of millions of people with diabetes worldwide. The InsuJet™ system is approved in 42 countries.
Average Trading Volume: 149,167
Technical Sentiment Signal: Sell
Current Market Cap: C$12.49M
Find detailed analytics on NGMD stock on TipRanks’ Stock Analysis page.